Concord Biotech Ltd (CONCORDBIO)
₹1,248.50
Mkt cap
₹14,019 Cr
P/E ratio
58.20
P/B
6.47
Div yield
0.56%
ROE
12.60%
ROCE
17.40%
EPS (TTM)
₹21.45
Book value
₹193
52W range
1,015–1,944
Sector
Healthcare
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. [1]
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBearish
52-week range
−35.77% from high₹1,249
₹1,015+23.03% from low₹1,944
Current
₹1,248.50
Prev close
₹1,248.00
Day
+0.04%
Price performance
1D
+0.04%
1W
−6.48%
1M
−2.92%
3M
+22.86%
6M
−0.73%
1Y
−34.99%
YTD
−4.80%
Financials
FRevenue, profit & margin
P/E ratio
58.2×
CONCORDBIO is 67% above the sector median of 34.9×
CONCORDBIO58.2×
Sector median34.9×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 273 | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | |
| Expenses | 144 | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 | 204 | |
| Operating Profit | 129 | 72 | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 | 122 | |
| OPM % | 47% | 37% | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% | 38% | |
| Other Income | 12 | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 | 16 | |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 19 | |
| Profit before tax | 126 | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 | 118 | |
| Tax % | 26% | 25% | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | |
| Net Profit | 94 | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 | 90 | |
| EPS in Rs | 8.94 | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 | 6.48 | 8.60 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.26% · closed higher next day 5 of last 12
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 6 Sept '23◦ | 9 Nov '23 | 9 Feb '24 | 24 May '24 | 9 Aug '24 | 12 Nov '24 | 14 Feb '25 | 29 May '25◦ | 8 Aug '25◦ | 13 Nov '25◦ | 11 Feb '26◦ | 29 May '26◦ |
| Earnings day | −2.22% | +4.03% | −1.23% | −0.52% | −2.01% | −1.10% | −19.86% | +4.90% | +0.38% | +2.77% | −1.28% | +0.96% |
| +1 day | +0.76% | −1.66% | −2.66% | −1.26% | −4.72% | −1.55% | −20.33% | +9.15% | +3.15% | +2.98% | −4.85% | +10.94% |
| +5 days | −0.18% | −3.35% | −0.77% | +0.29% | +3.57% | +5.75% | −21.85% | +15.58% | +3.05% | −2.13% | −10.24% | +13.84% |
| +15 days | +7.69% | +1.50% | +0.24% | +4.89% | +9.40% | +16.75% | −20.58% | +10.22% | +6.31% | −3.45% | −3.02% | +27.25% |
| +30 days | +15.06% | +13.71% | +1.49% | +15.76% | +50.26% | +14.99% | −19.66% | +8.18% | +1.98% | −8.40% | −18.19% | +26.29% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 7.55 Per Share | 7.55 | 24 Jul '26 | 24 Jul '26 |
Shareholding
Sas of Mar 202644.08%Promoter
Promoters44.08%
FIIs7.79%0.21
DIIs9.22%0.36
Public38.90%0.15
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.73 | 4,68,821 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.64 | 1,93,164 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.52 | 1,69,902 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.51 | 1,16,132 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.26 | 1,15,376 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.04 | 1,13,977 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.29 | 1,05,054 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Concord Biotech | ₹1,338.90 | 58.19 | 14,019 | 0.56% | 90 | −36.58% | 326 | −24.19% | 17.43% |
| Median: 156 Co. | ₹434.68 | 34.89 | 2,013 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DConcall transcripts27
TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024PPTJun 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Jul - Newspaper Advertisement for Notice of 41st Annual General Meeting, Book Closure and Remove e-voting informationIntimation Of Record Date And Book Closure Date 7 JulBusiness Responsibility and Sustainability Reporting (BRSR) 7 Jul - Filed BRSR for FY 2025-26 as part of the 41st Annual Report.Reg. 34 (1) Annual Report. 7 JulNotice Of 41St Annual General Meeting Of The Company For The Financial Year 2025-26 7 Jul